Management of sudden hearing loss with hyperbaric XXXX therapy.

@entity1 @entity26 @entity1274 @entity392 @entity288
@entity1274 ( @entity1274 ) is defined as the @entity1274 of a minimum of 30 dB in at least three frequencies for three days or more. This study aims to evaluate the clinical efficacy of hyperbaric @entity26 therapy (HBO2) in the management of @entity1274 . MATERIAL-METHODS: @entity1 with @entity1274 received treatment including oral @entity288 and HBO2. HBO2 protocol included five phases of five sessions each. @entity1274 was assessed by measuring the tonal audiogram before and after each phase. @entity392 was assessed using a questionnaire and a visual analogue scale at the beginning and the end of the study. Secondary assessment points included changes in the intensity and the improvement of @entity392 . RESULTS: 56 @entity1 were included in the study. All @entity1 completed Phases I and II of HBO2, 43 completed Phase III, 13 completed Phase IV, and six completed all five phases. Overall, a significant improvement was noted between the initial and final audiogram after HBO2 (p < 0.001). @entity392 evaluation score, intensity and related problems were also significantly reduced (p < 0.001). CONCLUSION: This study affirms previous findings that the use of HBO2 and vasodilators are efficacious in the treatment of @entity1274 . Our findings also suggest benefit for the treatment of @entity392 .
